(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2...n of the skin that affects more than 80 percent of...tress has often been cited // as a source of acne,... Twenty-two university students participated in th...one academic examination within the time of the st...
...ertaken at Wake Forest University Baptist Medical ... signs after research in monkeys suggested //that ... fact affect heart attack severity. At an annual...se Society in Washington, D.C. today, Dr. J. Koudy...
... report more than half a million women in developi... the Partnership for Safe Motherhood and Newborn H...nd the world to ensure that a woman does not die w...eport indicates that the needs are wide-ranging - ...
...run by nurses and dieticians have been found effec...ther analysis // has shown they work only when the...esterol-lowering drugs. Researchers looked at a pr...medications from their physicians and were only “c...
Other Medicine News:Health News:Hormone therapy may affect heart attack severity in women 2Health News:WHO acts to reduce the maternal death toll 2(Date:9/4/2008)... Updated Survival Data for Ipilimumab...swire-FirstCall/ -- Medarex, Inc.,(Nasdaq: MEDX )...ipilimumab,an investigational anti-CTLA-4 antibod...presentations at the 33rd Congress of the European...ptember 12-16, 2008 in Stockholm.,Many of the foll...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Tw...ge Clinical Data Release in November 2008, BRIDGE...maceuticals,Inc., a specialty pharmaceutical comp... metabolic disease, today announced the appointmen...rd of directors., Peter Garrambone,s career inclu...
(Date:9/3/2008)... NANJING, China, Sept. 3 /PRNewswire-FirstCal...a leading manufacturer and supplier of,branded gen...ted,anti-cancer biotech product Endu (also known a...s of Endu Phase IV clinical study., At the reques...al study,to further validate the safety and therap...
(Date:9/3/2008)... September is National Vascular Diseas.../- Diffusion Pharmaceuticals,LLC, a c...zing new drugs,for the treatment of unmet medical ... patients in a Phase I/II clinical trial of its le...The trial, designated NCT00725881,on the clinicalt...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees 136 1UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees 136 2Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business 134 1Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business 134 2Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business 134 3Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing 125 1Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing 125 2Soccer burns more fat than jogging 123 1Soccer burns more fat than jogging 123 2Soccer burns more fat than jogging 123 3...dpoints, Wake After Sleep Onset and Total Sleep,Ti... to Persistent,Sleep, Were Met at Both Doses, HAMB...RNewswire-FirstCall/ -- Evotec AG announced today ...clinical trial of EVT 201,in patients with chronic...llosteric modulator (pPAM) of the GABAA receptor c...
...2007 - An established second-line,drug for chroni...n,given to newly diagnosed patients as their first...ts from a Phase II clinical trial,at The Universit...ts taking dasatinib achieve complete cytogenetic r...es this disease - more,rapidly than we,ve observed...
Other Medicine Technology:Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201 2Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201 3Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201 4Dasatinib Shows High Early Response Rate as First Treatment for,Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report 2Dasatinib Shows High Early Response Rate as First Treatment for,Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report 3...ment introduction. The design of the introducer fe...ition profile between the introducer sheath and in...h fascial tissue and strictured areas. Proximal re...ducer sheath and introducer dilator during sheath ...
Used for catheter or instrument introduction. The dual knobs allow the sheath to be peeled away and removed. The maximum diameter of the catheter or instrument to be introduced should be measured to
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use.
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: